SC291
Phase 1Active 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lupus Erythematosus
Conditions
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Trial Timeline
Apr 29, 2024 → Mar 1, 2028
NCT ID
NCT06294236About SC291
SC291 is a phase 1 stage product being developed by Sana Biotechnology for Lupus Erythematosus. The current trial status is active. This product is registered under clinical trial identifier NCT06294236. Target conditions include Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus).
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06294236 | Phase 1 | Active |
| NCT05878184 | Phase 1 | Active |
Competing Products
20 competing products in Lupus Erythematosus